MedTrace Logo

Effect of Acetazolamide on Central Sleep Apnea Related to Opium Consumption

NCT02371473 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2018-05-08

No results posted yet for this study

Summary

Acetazolamide improves central sleep apnea related to opium consumption.

Conditions

  • Central Sleep Apnea, Secondary

Interventions

DRUG

Acetazolamide-placebo

The patients in this arm are given Acetazolamide mg for six days and after 2 weeks washout they are given placebo for six days.

DRUG

Placebo-acetazolamide

The patients in this arm are given placebo for six days and after 2 weeks washout they are given Acetazolamide for six days.

Sponsors & Collaborators

  • Masih Daneshvari Hospital

    collaborator OTHER

  • Shahid Beheshti University of Medical Sciences

    lead OTHER

Principal Investigators

  • Parisa Adimi, MD · Shahid Beheshti University of Medical Sciences

  • Moein Forughi, MD · Shaheed Behesti Medical University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-11-30
Primary Completion
2018-06-30
Completion
2018-12-31

Countries

  • Iran

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02371473 on ClinicalTrials.gov